-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin Biotech targets mid-2026 unblinding of 45-patient interim data in Phase 2B/3 MIRACLE Annamycin AML trial

Reuters·03/19/2026 12:36:01

Please log in to view news